Biofrontera Achieves Database Lock for Ameluz PDT Studies in AK and Acne

jueves, 8 de enero de 2026, 9:01 am ET1 min de lectura
BFRI--

Biofrontera announced the successful database lock of two clinical studies evaluating Ameluz PDT for actinic keratosis and acne vulgaris. The database lock marks an important milestone ahead of several anticipated data and regulatory events in 2026. Ameluz PDT is a photodynamic therapy developed by the company for the treatment of skin disorders. The two studies will support key regulatory milestones for Ameluz PDT in both indications.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios